Prevention of Postoperative Delirium With Donepezil

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00220896

Enrollment

Registered

2005-09-22

Start date

2006-01-31

Completion date

2009-03-31

Last updated

2011-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitively Normal Elderly Individuals

Keywords

Delirium, Prevention, Donepezil

Brief summary

Patients undergoing hip or knee joint replacement at the age of 70 years or above who are cognitively unimpaired will receive donepezil or matching placebo before (over 5-7 days), during and after (over 7 days) surgery. The incidence of delirium will be monitored at 3 days, 7 days, and 49 days following surgery. We hypothesize that the incidence of delirium can be lowered from 20 per cent to 10 per cent by the intervention.

Interventions

DRUGDonepezil

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

70 Years to No maximum

Healthy volunteers

Inclusion criteria

* Cognitively healthy, elective hip or knee replacement

Exclusion criteria

* Ongoing cholinergic treatment, dementia, delirium, acute physical illness

Design outcomes

Primary

Measure	Time frame
Incidence of delirium	—

Secondary

Measure	Time frame
Cognitive performance	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026